相关实验视频

Updated: Jul 25, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

KLHL7通过降解RASA2来促进肝细胞癌的进展和分子治疗耐药性

Lin Chen¹, Yun Li¹, Yongheng Chen¹

¹Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.

|June 28, 2023

概括

这项研究表明,KLHL7的高表达促进了肝细胞癌 (HCC) 的进展. 与伦瓦替尼一起抑制KLHL7有效地向HCC,将KLHL7确定为这种侵袭性癌症的潜在治疗标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

肝细胞癌 (HCC) 是一种具有有限治疗选择的侵袭性恶性瘤.
患有HCC的患者往往对传统药物治疗有抗性.
了解推动HCC进展的分子机制对于开发有效疗法至关重要.

研究的目的:

研究KLHL7在肝细胞癌 (HCC) 发展和进展中的作用.
阐明KLHL7影响HCC的分子机制.
评估KLHL7作为HCC治疗的潜在治疗标.

主要方法:

对HCC组织中KLHL7表达的分析以及与患者预后的相关性.
在体外和体内实验来评估KLHL7在HCC中的功能作用.
确定RASA2作为KLHL7的基质,并调查其无化和降解途径.
结合疗法实验涉及KLHL7抑制和伦瓦提尼布 in vivo.

主要成果:

在HCC中,KLHL7表达显著上调,并与患者预后不佳有关.
在体外和体外模型中,KLHL7的过度表达促进了HCC的发展.
发现KLHL7针对RASA2 (一种RAS GTPase激活蛋白) 进行K48相关的多基化和蛋白质体降解.
抑制KLHL7与伦瓦替尼结合,在体内表现出强大的抗瘤活性,对抗HCC.

结论:

通过RASA2降解调节RAS-MAPK通路,KLHL7在促进HCC进展方面发挥着至关重要的作用.
向KLHL7,特别是与伦瓦提尼布联合使用,代表了肝细胞癌的有前途的治疗策略.
KLHL7被确定为对抗HCC的新型治疗点.

关键词:

生物科学生物科学癌症癌症癌症癌症分子生物学分子生物学

更多相关视频

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Small GTPases - Ras and Rho

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...